Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 20;8(1):e000217. doi: 10.1136/jitc-2019-000217

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Diagnostic assessment, treatment, and clinical monitoring of the patient with CDC. (A) Pretreatment assessment of primary CDC tumor and bone metastasis lesion, as determined by pathological examination of H&E-stained needle biopsies. (B) Timeline presentation of the treatment dates of personalized neoantigen peptide vaccination and NRT infusion. (C, D) Timeline of kidney and lumbar vertebra CT scans and the corresponding tumor size during neoantigen-based immunotherapy. The red arrows indicate the primary tumor lesion (upper panel) and metastatic tumor lesions (lower panel). CDC, collecting duct carcinoma; NRT, neoantigen-reactive T cell.